Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Immune Response in NHL
NCT00090038Phase 4Completed
- Sponsor
- Biogen
- Start
- Oct 2003
- Primary completion
- Jun 2007
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 4, open-label trial of rituximab in Non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Biogen. Primary endpoint: Immunological recall response to tetanus vaccine at 8.5 months. Started Oct 2003; status: completed.
02
Drugs
rituximab
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00090038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090038.